Zimmerman Ronald is Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares

0
38

 

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), PLx Pharma Inc. (NASDAQ:PLXP) reported that Zimmerman Ronald has picked up 384,681 of common stock as of 2017-06-22.

The acquisition brings the aggregate amount owned by Zimmerman Ronald to a total of 384,681 representing a 4.37% stake in the company.

For those not familiar with the company, PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

A glance at PLx Pharma Inc. (NASDAQ:PLXP)’s key stats reveals a current market capitalization of $53.84 Million based on $8.68 Million shares outstanding and a price at last close of $6.30 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-06-14, Jorden picked up 32,727 at a purchase price of $6.88. This brings their total holding to 151,913  as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an PLx Pharma Inc. (NASDAQ:PLXP) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.